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In The Netherlands, the incidence and prevalence of heart failure are rising as is the case in most other European countries. Overall, there
are 200,000 patients with heart failure in The Netherlands and around 25,000 hospitalisations annually with a discharge diagnosis of heart
failure. Most of these patients are managed in primary care, often together with a cardiologist.
There is an active guideline program in different professional organisations (e.g. general practitioners, cardiologists) and in 2002 a
collaborative multidisciplinary guideline for management of chronic heart failure was developed. However, there is clearly room for
improvement in the adherence to these guidelines both with regard to the diagnosis and the treatment of HF patients. For example, ACE-I and
h-blockers are still under-prescribed. In particular, the more severely ill patients seem to be under treated. At present, general practitioners
and cardiologists differ in their views on heart failure, resulting in differences in diagnosis and management. In addition to the
multidisciplinary guidelines, several other initiatives have been developed to improve outcomes in these patients, such as rapid access clinics
and outpatient heart failure clinics.
D 2005 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
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Although the borders between different European
countries are becoming less strict, there are still notable
differences in health care delivery between countries. InFailure 7 (2005) 371–375d by Elsevier B.V. All rights reserved.
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European Journal of Heart Failure on management of
heart failure in different European countries, including
Poland, France, and Sweden [1–3]. The Netherlands has
made a substantial contribution to many HF trials,
managed by the Dutch working group in cardiology
centers and it seems that the health care providers in The
Netherlands are quick to adapt to new developments [4].
In this paper, the current status and developments in the
management of heart failure in The Netherlands are
discussed.2. Epidemiology of heart failure in The Netherlands
Cardiovascular diseases are still the main cause of
premature death in The Netherlands. In 2002 total
mortality was 142,355, of which 34% was due to
cardiovascular diseases. Compared to the European
average, mortality from circulatory diseases in The
Netherlands is slightly below average. Other major causes
of death are cancer (28%) and respiratory disease (10%)
[5].
In line with most countries in Europe, prevalence and
incidence of HF are high and the number of patients with
chronic HF is growing. Recently, results of the Rotterdam
study (based on 7983 persons over 55 years of age)
suggested, that in individuals aged 55, almost 1 in 3 will
develop heart failure during their remaining life span [6].
The same study determined point prevalences of 6.4%,
6.7% and 7.0% in 1997, 1998, and 1999, respectively.
The mean age of the study population increased from
73.3 years in 1997 to 74.5 years in 1999. The prognosis
of participants with heart failure was poor, with a 5 year
survival of 35% [6].
Costs related to cardiovascular diseases amounted to
10.1% of the total costs of the Dutch Health Care System
in 1999, of which 28% was related to stroke, 26% to
ischemic heart disease, and 8% to heart failure [5].
In 1999, 24,868 hospitalisations were registered with a
discharge diagnosis of heart failure [7], which equates to
about 16.1.admissions per 10,000 inhabitants. Readmis-
sion rates for HF in The Netherlands are lower compared
to other European countries. However, at the same time
the duration of stay is longer than in other European
countries [8]. In The Netherlands, readmission rates are
used as the official indicator of quality of HF care by the
Dutch Health Inspectorate.
Heart failure severely affects the quality of life of
patients. From international data it is known that
compared to the general population and compared to
patients with other chronic diseases, heart failure patients
have a significantly decreased quality of life [9]. Several
studies in the Dutch population have found that different
domains in the area of quality of life are affected by heart
failure [10–12].3. Organisation of health care services in TheNetherlands
The Dutch health care system is a gate-keeping system,
where patients can only consult a specialist/cardiologist
after referral from a general practitioner (GP). GPs are self-
employed and each patient is registered with one GP.
Cardiologists are usually also self-employed but hospital-
based and work in partnerships, with the exception of
academic hospitals which employ specialists with multiple
tasks such as patient care, teaching, and research.
At present, health insurance in The Netherlands is a
mixed public–private system. The majority of people (61%)
are covered by the public system, while 37% have private
insurance, and 2% of the population have no insurance. In
principle, all health care costs for chronic heart failure are
covered, although private insurance packages often include
deductibles. In the near future, more co-payment strategies
will be implemented, while a proposal for a major system
change is at present being discussed by politicians.
Reimbursement of costs for chronic heart failure care is
unlikely to be affected, because accessibility when needed
will remain the key issue.4. Management of patients with heart failure
Since the end of the eighties The Netherlands have had
the active guideline program of the Dutch College of
General Practitioners (NHG) and the Dutch Institute for
Health Care (CBO). The first NHG-guideline on diagnosis
and treatment of heart failure in General Practice was
published in 1995, this was followed in 2002 by a
collaborative guideline produced by GPs and cardiologists,
which covered diagnosis, treatment, and care [13]. This new
guideline is mostly in line with the ESC guideline [14], the
major difference being that The Netherlands sees a greater
role for diuretics. While in the ESC guideline diuretics are
recommended only in combination with ACE-inhibitors, in
The Netherlands, by contrast, diuretics explicitly should not
be stopped and ACE-inhibitors are recommended in
addition. In the earlier version of the NHG guideline,
diuretics were recommended always as the first drug, also
for diagnostic reasons.
4.1. Diagnosis of heart failure
In primary care, a history of myocardial infarction or
hypertension, symptoms of dyspnoea, peripheral oedema,
the presence of pulmonary crepitations, and elevated
jugular venous pressure are qualified as important clinical
signs and symptoms in diagnosing heart failure. Chest
radiography and electrocardiography are used most often
to support diagnosis. In general, GPs tend to diagnose
heart failure on clinical grounds, supported by a diagnostic
trial of diuretics [15]. In the European IMPROVEMENT-
HF study in primary care, only 10% of Dutch primary care
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while in effect 84% of those patients had Echo results
available [16]. This may be a consequence of the older GP
guideline (1995) which states that echocardiography is of
limited value for the diagnosis of heart failure (though the
newer guideline does indicate the need for echocardiog-
raphy), as well as poor GP access to echocardiography.
Cardiologists all rely on echocardiography along with
other diagnostic tests. A few hospitals offer a heart failure
diagnosis and treatment advice service to GP’s in a drapid-
access-clinicT. More recently BNP/NTproBNP tests have
been introduced as diagnostic aids in several hospitals in
The Netherlands.
4.2. Treatment of heart failure
The international indicator of quality of HF treatment is
the percentage of HF patients who receive ACE inhibitors
(ACE-I) or h-blockers. In The Netherlands prescribing of
ACE-I in primary care in 2000 varied from 18.3% in a
national study [17] to almost 60% in the Improvement-HF
study in 1999/2000 [19]. Prescribing at hospital discharge
was found to be about 70% [18]. ACE-I use has remained
stable between 1996 and 2000 with a slight increase from
38.6 to 42.6% [20]. Prescribing of angiotensin-II antagonists
and spironolactone increased over the same period, although
the use of these drugs was still comparatively low in 2002
(9.0% and 11.4% of HF patients, respectively). h-Blocker
use is still low with 26% of primary care patients and 37%
of hospitalized patients receiving this treatment [18,21].
Optimal heart failure treatment differs depending on the
severity of the disease and usually involves a combination
of drugs (Table 1) [19]. As is to be expected, combination
therapy increases as disease severity increases. However,Table 1
Combination regimes: percentage of patients by NYHA class treated with the majo
NYHA 1 NYHA 2
None 22.4 (15.3 to 29.4) 8.3 (4.9 to 11.7
Diuretic monotherapy 3.7 (0.5 to 6.9) 8.7 (5.2 to 12.2
ACEI monotherapy 8.2 (3.6 to 12.9) 8.7 (5.2 to 12.2
h-blocker monotherapy 23.1 (16.0 to 30.3) 11.5 (7.5 to 15.4
Diuretic and ACEI 3.7 (0.5 to 6.9) 13.4 (9.2 to 17.6
Diuretic and h-blocker 6.0 (2.0 to 10.0) 5.9 (3.0 to 8.8)
Diuretic and digoxin 0.7 (0.1 to 4.1) 3.2 (1.0 to 5.3)
ACEI and h-blocker 15.7 (9.5 to 21.8) 9.1 (5.5 to 12.6
Diuretic and ACEI and h-blocker 3.0 (1.2 to 7.4) 9.5 (5.9 to 13.1
Diuretic and ACEI and digoxin 6.0 (2.0 to 10.0) 7.5 (4.3 to 10.8
Diuretic and ACEI and spironolactone 1.5 (0.4 to 5.3) 2.0 (0.3 to 3)
Diuretic and ACE and h-blocker
and digoxin
1.5 (0.4 to 5.3) 1.6 (0.6 to 4.0)
Diuretic and ACEI and digoxin
and spironolactone
0 1.2 (0.4 to 3.4)
Othera 4.5 (1.0 to 8.0) 9.4 (5.9 to 13.1
Total 100 (n=134) 100 (n=252)
95% confidence intervals are presented in parentheses (adapted from Ref. [19]).
a Other cardiovascular agents in addition to those included in this table may hav
than 5% of heart failure patients in each NYHA class.this study also found evidence that more severely ill patients
(NYHA III and IV) had a higher risk of being undertreated,
than less severely ill patients [19].
4.3. Differences between GPs and specialists in manage-
ment of HF patients
There are clear differences between General Practitioners
and cardiologists in their views, and practices on HF. The
basis for these differences is the type of guideline used.
While specialists primarily rely on the international liter-
ature and policies in their own hospital departments, general
practitioners rely on the Dutch national GP guidelines, and
regional guidelines [22]. GPs and cardiologists also differ in
their diagnosis and management of HF. While GPs tend to
diagnose more on clinical grounds, cardiologists use more
diagnostic investigations [15].
GPs and cardiologists also treat different patient pop-
ulations. In general, GPs treat more women and more
elderly patients, whereas cardiologists treat more men, their
patients are on average younger, and with more ischemic
heart disease as a co-morbidity. Patients treated by
cardiologists are more likely to receive ACE-I, h-blockers,
spironalactone, and angiotensin-II antagonists, while most
GP patients receive a diuretic [21]. One might therefore
expect, that GP patients who have been referred to a
cardiologist are more likely to receive an ACE-I; however, a
recent study found that this was not true and neither was
there an effect of prior hospitalisation [22]. The only
positive predictor was the involvement of a specialised HF
clinic, which resulted in more ACE-I use. The use of ACE-I
in GP cannot be predicted by patient and clinical character-
istics, with the exception of age (the older the less ACE-I),
and gender (men get ACE-I more often).r treatment regimes (diuretics, ACEI, h-blockers, digoxin, or spironolactone)
NYHA 3 NYHA 4 All heart failure patients
) 0.9 (0.2 to 3.1) 0.7 (0.1 to 3.7) 7.0 (5.2 to 8.8)
) 9.9 (6.1 to 13.8) 10.7 (5.7 to 15.6) 8.6 (6.4 to 10.2)
) 3.0 (0.8 to 5.2) 0.7 (0.1 to 3.7) 5.3 (3.7 to 6.9)
) 4.7 (2.0 to 7.5) 2.0 (0.7 to 5.7) 9.6 (7.5 to 11.7)
) 21.1 (15.9 to 26.4) 18.7 (12.4 to 24.9) 15.1 (12.6 to 17.6)
4.7 (2.0 to 7.5) 2.0 (0.7 to 5.7) 4.8 (3.3 to 6.3)
4.7 (2.0 to 7.5) 5.3 (1.7 to 8.9) 3.6 (2.3 to 5.0)
) 3.9 (1.4 to 6.4) 0.7 (0.1 to 3.7) 7.0 (5.2 to 8.8)
) 8.2 (4.7 to 11.7) 7.3 (3.2 to 11.5) 7.5 (5.7 to 9.4)
) 11.2 (7.1 to 15.3) 14.7 (9.0 to 20.3) 9.8 (7.7 to 11.8)
3.9 (1.4 to 6.4) 10.7 (5.7 to 15.6) 4.2 (2.7 to 7.6)
6.0 (3.0 to 9.1) 3.3 (0.5 to 6.2) 3.3 (2.0 to 4.5)
3.4 (1.1 to 5.8) 6.7 (2.7 to 10.7) 2.7 (1.6 to 3.9)
) 14.4 (9.7 to 18.7) 16.5 (10.7 to 22.6) 11.5 (9.2 to 13.7)
100 (n=232) 100 (n=150) 100 (n=769)
e been used. Other combinations not shown in the table were used by less
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Patients with HF and/or left ventricular dysfunction form
a heterogeneous group. Patients with HF diagnosed and who
are being treated within the health care system, merely
represent the tip of the iceberg [24]. Data from the European
IMPROVEMENT-HF study indicate that the initial diag-
nosis of HF was made by the patient’s GP for 42.1% of the
patients, by hospital cardiologist for 33.7%, and for 9.4% by
another GP [16] (Fig. 1).
As care provided to HF patients is related to the underlying
cause and individual circumstances, organisation of care may
differ. For example, HF caused by a congenital heart disease
may require highly specialised cardiac care, while in contrast,
elderly patients with HF due to systolic dysfunction are
mostly treated and cared for by their GP’s. Professionals who
may be involved in treatment and care of HF patients are: GP,
cardiologist, heart failure nurse, home care, internist,
dietician, pharmacist, social worker, psychologist, physical
therapist, geriatrician, and nurse practitioner in GP.
The involvement of the GP is variable and depends on the
stage of the disease. Currently, the GP is mostly involved at
the beginning and the end (terminal) stage of the disease [24].
The majority of HF patients are managed in primary care,
though often together with a cardiologist. Usually the cardio-
logist sees a stable HF patient once or twice a year, while the
GP provides daily care throughout the year. In a recent study
in the North of The Netherlands, 33% of HF patients in
General Practice had seen a cardiologist in the previous year
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Fig. 1. Flowchart of patient pathdetectable from treatment data; in many cases the cardiologist
will initiate new treatment that is then continued by the GP
[25]. No exact data can be given, because such practices vary
depending on the cardiologists and GPs involved.
Several initiatives have been developed to improve
health outcomes in patients, of which HF management
programs are the most important. The first heart failure
clinic started in 1994 and similar initiatives started soon
after. Although there is still a lack of evidence in The
Netherlands for the beneficial effects of HF management
programs, numbers are increasing steadily (42% of all
hospitals had a HF management program in 2000, this had
increased to 60% in 2003) [26,27]. Most programs are
organized as outpatient clinics. Cardiologists and nurses
are involved in all HF programs, other professionals
involved include: physical therapists (47%), general
practitioners (29%), and dieticians (59%). All the programs
offer follow-up after discharge from hospital and in 95%
of the programs patients have increased access to a health
care provider. Other important components of HF pro-
grams are (restricted) physical examination (90%) and
optimization of medical treatment (65%) by the HF nurse,
exercise programs (43%), behavioural interventions (68%),
psychosocial counselling (64%), patient education (88%),
and support for informal caregivers (59%) [27]. There is
no uniformity of funding for programs. Seventy percent of
institutions finance their programs at least partly them-
selves, but are often supported by the pharmaceutical
industry (27%) and health insurance companies (35%).






 at outpatient 
department
way through the system.
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Netherlands [28].
Other programs that provide specialised care for HF
patients by a pharmacist [29] or home care [30] are still
scarce and require further development. There is great
diversity in the content, intensity, professionals involved,
and financing of these programs. In addition, there is a
lack of formal agreements about responsibilities, compe-
tencies and jurisdiction. There is currently lively debate
about the autonomy of the HF nurse regarding lifestyle
counselling and prescription of medication (which is not
legally allowed) and the optimal dchain of careT for
patients with heart failure.References
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